Article
Oncology
Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Summary: The study evaluated the efficacy of ponatinib for advanced gastrointestinal stromal tumors (GIST) and found that ponatinib demonstrated activity, particularly in KIT ex11-positive disease. There was a strong concordance of primary KIT mutations between plasma and tumor. Resistance was associated with the emergence of secondary mutations. Ponatinib was ineffective in patients with KIT exon 9 primary mutations. The safety profile was consistent with previous studies.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Eline L. Giraud, Loek A. W. de Jong, Erik van den Hombergh, Suzanne E. J. Kaal, Nielka P. van Erp, Ingrid M. E. Desar
Summary: This study aimed to investigate the distribution of imatinib within gastrointestinal stromal tumours (GISTs) and its correlation with plasma concentrations. The results showed that imatinib accumulated in tumour tissue with higher concentrations compared to plasma, but no clear distribution pattern within the tumour could be identified. The variability in tumour concentration was higher than that in plasma concentration. There was no correlation between imatinib concentrations in tumour tissue and treatment response.
Article
Biochemistry & Molecular Biology
Takuma Hayashi, Ikuo Konishi
Summary: Through cancer genome testing, a germline pathogenic variant of the KIT gene was detected in a 32-year-old male patient with advanced GISTs, confirming the diagnosis of familial multinodular GIST. Treatment with imatinib resulted in long-term regression of GISTs in this patient. Therefore, cancer genome testing can be used to diagnose malignant tumors and select new therapeutic agents for advanced malignancies.
Article
Oncology
You-Zhu Wei, Zhi-Bin Cai, Chen-Long Zhu, Yan-Ming Zhou, Xiao-Feng Zhang
Summary: The study evaluated the long-term survival outcomes of patients with duodenal GIST who underwent radical resection (RR) or limited resection (LR). Results showed that surgical modalities did not have a significant impact on long-term survival outcomes, which should mainly depend on tumor size and location.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Christos Vallilas, Panagiotis Sarantis, Anastasios Kyriazoglou, Evangelos Koustas, Stamatios Theocharis, Athanasios G. Papavassiliou, Michalis V. Karamouzis
Summary: Gastrointestinal stromal tumors (GISTs) are the most common types of malignant mesenchymal tumors in the gastrointestinal tract, with treatment options including drugs and immunotherapy, some patients have gene mutations, and drug resistance is becoming more common.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Sara Renberg, Yifan Zhang, Fredrik Karlsson, Robert Branstrom, Jan Ahlen, Li Jalmsell, Christina Linder-Stragliotto, Felix Haglund de Flon, Andri Papakonstantinou
Summary: This retrospective study investigated the use of neoadjuvant imatinib in patients with gastrointestinal stromal tumors (GIST), showing that it can effectively reduce tumor size and minimize the extent of surgery, especially for tumors in the stomach or small intestine.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Szymon Macioszek, Danuta Dudzik, Rafal Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schoffski, Michal J. Markuszewski
Summary: In this study, integrative metabolomic and transcriptomic analyses were performed to investigate the impact of imatinib treatment on tumour biochemical processes. The results revealed differential metabolite and gene expression profiles, indicating changes in pruine and pyrinridine metabolism, butanoate metabolism, as well as alanine, aspartate, and glutamate metabolism. These findings provide insights into the mechanisms of imatinib's anti-tumour activity and suggest a potentially novel approach for enhancing its efficacy or re-sensitizing imatinib-resistant tumours.
TRANSLATIONAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Aldo Di Vito, Gloria Ravegnini, Francesca Gorini, Trond Aasen, Cesar Serrano, Eva Benuzzi, Emma Coschina, Sarah Monesmith, Fabiana Morroni, Sabrina Angelini, Patrizia Hrelia
Summary: Gastrointestinal stromal tumors (GISTs) are rare mesenchymal sarcomas treated with tyrosine kinase inhibitors (TKIs). The first-line TKI, imatinib, usually only results in a partial response or stable disease, and resistance is common. Adaptive mechanisms and resistant subclones contribute to imatinib resistance in GISTs. Secondary mutations and alternative signaling pathways may play a role in resistance to novel multi-targeted TKIs, such as ripretinib. The review discusses the complex nature of imatinib resistance in GISTs and suggests potential mechanisms that contribute to the modest efficacy of ripretinib and other anti-GIST agents.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Tahsin M. Khan, Emily A. Verbus, Alexander J. Rossi, Jonathan M. Hernandez, Jeremy L. Davis, Brian A. Coakley, Andrew M. Blakely
Summary: Wild-type KIT and PDGFRA gastrointestinal stromal tumors are rare and have limited treatment options. This study analyzed data from a large national database to identify factors influencing overall survival, finding that tumors in the small intestine and with high mitotic count were associated with decreased OS. Surgery remains the primary treatment modality for wild-type GIST.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Hyunjee. V. V. Kwak, Katherine. J. J. Tardy, Andrew Allbee, Kristen Stashek, Ronald. P. P. DeMatteo
Summary: Gastrointestinal stromal tumor (GIST) is usually caused by sporadic mutations in the KIT or PDGFRA genes, but can also be caused by germline mutations. Surgical resection is critical for patients with germline GIST, especially in the stomach, since most tumors do not respond to tyrosine kinase inhibitors. However, there are no formal guidelines for timing or extent of surgical resection. This article discusses the challenges and principles of surgery in patients with germline GIST, with a case study of a patient harboring a germline KIT 579 deletion.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Cesar Serrano, Rosa Alvarez, Juan Antonio Carrasco, Gloria Marquina, Jeronimo Martinez-Garcia, Virginia Martinez-Marin, Maria angeles Sala, Ana Sebio, Isabel Sevilla, Javier Martin-Broto
Summary: Gastrointestinal stromal tumor (GIST) is a common malignant neoplasm of mesenchymal origin, and a successful model for targeted cancer therapies. The use of tyrosine kinase inhibitors targeting KIT/PDGFRA has greatly improved survival in both localized and advanced stages, despite previous resistance to systemic therapies. These guidelines, developed by the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS), provide an updated consensus for diagnosing and treating GIST patients, emphasizing the importance of multidisciplinary teams in specialized centers.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Review
Cell Biology
Jiehan Li, Shuning Guo, Zhenqiang Sun, Yang Fu
Summary: In this review, the role of noncoding RNAs (ncRNAs) in drug resistance of gastrointestinal stromal tumor (GIST) was summarized. The study found that ncRNAs play important roles in the resistance of GIST, mainly through regulating mechanisms such as oxidative phosphorylation, autophagy, apoptosis, drug target changes, and signaling pathways.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anbu Liu, Shaoting Zhang, Ming Wang, Liangying Zhang, Shidong Xu, Ahmad Nasimian, Shujing Li, Sien Zhao, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Hui Zhao, Julhash U. Kazi, Lijun Ma, Jianmin Sun
Summary: This study demonstrates that DDR1/2 contribute to KIT activation and enhance resistance to imatinib in GISTs, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.
MOLECULAR CARCINOGENESIS
(2023)
Article
Medicine, General & Internal
Nikolaos Vassos, Aristotelis Perrakis, Werner Hohenberger, Roland S. Croner
Summary: Surgical management of duodenal GIST depends on tumor size and origin, with local resection being a preferred choice. PD group had larger tumors, higher mitotic count, longer operative time, hospital stay, and postoperative complications rate; patients with tumor > 5 cm and high-risk potential may have an increased risk of disease recurrence.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Daniel F. Pilco-Janeta, Alfonso Garcia-Valverde, David Gomez-Peregrina, Cesar Serrano
Summary: This review focuses on treatment options for advanced/metastatic GIST, with a specific emphasis on ripretinib and avapritinib, the two novel small molecule inhibitors approved by the FDA in 2020. Expert opinion highlights the need for new treatment options due to the modest benefits of second- and third-line therapies in metastatic GIST patients.
EXPERT OPINION ON EMERGING DRUGS
(2021)
Article
Mathematics, Applied
Sebastian Burciu
Summary: In this paper, it is shown that integral fusion categories with rational structure constants have a natural group of symmetries, given by the Galois group of their character tables. These symmetries are then used to generalize a well-known result of Burnside in the representation theory of finite groups. The main result establishes that any row in the character table of a weakly integral fusion category, corresponding to a non-invertible object, contains a zero entry.
JOURNAL OF ALGEBRA AND ITS APPLICATIONS
(2023)
Editorial Material
Oncology
Piotr Rutkowski, Sylvie Bonvalot
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paolo A. A. Ascierto, Mario Mandala, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Summary: This study is a randomized, three-arm, noncomparative phase II trial that aims to explore sequential immunotherapy and BRAF/MEK inhibition for patients with BRAFV600-mutant metastatic melanoma. The results show that sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Silvia Stacchiotti, Hans Roland Duerr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L. Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R. Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M. Seddon, Morena Shkcodra, Eric L. Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M. M. Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Michiel Van de Sande, Sebastian Bauer
Summary: Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive tumor that arises from the joints, bursa, and tendon sheaths. There are two types of TGCT: nodular and diffuse, with the former exhibiting a slow disease course and the latter showing locally aggressive behavior. Although not life-threatening, TGCT can cause chronic pain and negatively impact function and quality of life. CSFR1 inhibitors are effective in treating TGCT but are not widely available. The lack of guidelines and uncertainty in selecting appropriate therapy lead to inconsistent adoption of new treatments and suboptimal outcomes for patients. A global consensus meeting was held in June 2022 to develop evidence-based recommendations for the optimal management of TGCT.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Sergio Armando Zapata Bonilla, Marius Fried, Susanne Singer, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Karin Arndt, Martin Bornhaeuser, Jochen Schmitt, Markus K. Schuler, Martin Eichler
Summary: This study investigated predictors of limitations in work performance, odds of drop out of work, and odds of receiving a disability pension in sarcoma patients. It found that patients with abdominal tumors, older patients, high-grade patients, and those with longer time since diagnosis were more likely to receive a disability pension. Bone sarcoma patients and those who received both radiotherapy and systemic therapy had higher odds of dropping out of work. Work limitations were higher in women and increased with age, and patients with bone and fibrous sarcomas were more affected. Sarcoma treatment in the last 6 months increased work limitations. Identifying vulnerable groups in socioeconomic and disease categories is important for supporting these patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Geert Spierenburg, Floortje G. M. Verspoor, Jay S. Wunder, Anthony M. Griffin, Peter C. Ferguson, Matthew T. Houdek, David M. King, Richard Boyle, Robert Lor Randall, Steven W. Thorpe, Jacob I. Priester, Erik J. Geiger, Lizz van der Heijden, Nicholas M. Bernthal, Bart H. W. B. Schreuder, Hans Gelderblom, Michiel A. J. van de Sande
Summary: This study compared the short-term postoperative outcomes of one-stage and two-stage surgeries on both sides for diffuse-type tenosynovial giant cell tumors (D-TGCTs) of the knee. The results showed that one-stage surgery did not impair rehabilitation, and patients had a shorter hospital stay and no more complications.
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This article describes the impact of Tenosynovial giant cell tumor (D-TGCT) on patient-reported outcomes (PROs) based on the Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry. The study found that patients without active treatment strategy had lower pain levels and better quality of life at 1-year and 2-year follow-ups. On the other hand, patients receiving systemic treatment had higher pain levels when they changed treatment strategies. These findings highlight the significant impact of treatment strategies on patient quality of life.
Article
Cardiac & Cardiovascular Systems
Denis Fedorov, Robert Bauernschmitt, Jean-Pilippe Grunebaum, Stefan Bauer, Ralf Sodian, Eberhard von Hodenberg
Summary: This study aimed to evaluate the outcomes of redo-SAVR and TAVI-VIV for degenerated stentless bioprostheses. The results showed outstanding 30-day and 1-year survival rates for both procedures. Isolated redo-SAVR may be preferred in younger patients due to lower pacemaker implantation rates, while TAVI-VIV could be a method of choice for elderly patients with high operative risk.
THORACIC AND CARDIOVASCULAR SURGEON
(2023)
Article
Oncology
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou-Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valerie Laurence, Emmanuelle Bompas, Esma Saada-Bouzid, Corinne Delcambre, Francois Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud
Summary: Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Hans Gelderblom, Robin L. Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, Cesar Sanchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, Cesar Serrano, Neeta Somaiah, Ping Chi, Brooke Harrow, Claus Becker, William Reichmann, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich, INTRIGUE Investigators
Summary: In the INTRIGUE trial, there was no significant difference in progression-free survival between ripretinib and sunitinib for advanced gastrointestinal stromal tumour (GIST) patients. The study compared the impact of these treatments on health-related quality of life (HRQoL) and found that patients receiving ripretinib had better HRQoL during the dosing period compared to patients receiving sunitinib.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Martin Eichler, Susanne Singer, Leopold Hentschel, Beate Hornemann, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Sergio A. Zapata Bonilla, Marius Fried, Karin Arndt, Martin Bornhaeuser, Jochen Schmitt, Markus K. Schuler
Summary: This study aimed to determine the frequency of psycho-oncological service utilization among soft tissue sarcoma patients and investigate associated factors. It was found that female sex, younger age, higher education, and advanced disease stage were positively associated with increased utilization. Involvement of psycho-oncologists in the tumor board also increased the likelihood of service utilization.
Article
Oncology
Lennart Schardt, Moritz Kaths, Sebastian Bauer
Summary: Summary: Gastrointestinal stromal tumors (GIST) consist of various molecular subtypes with different treatment implications. Genotyping plays a crucial role in treatment decision-making. Adjuvant imatinib treatment is beneficial for patients with KIT exon 11 mutations and high risk of relapse. Evidence for this benefit is weaker for less frequent KIT genotypes, such as exon 9, 13, and 17 mutations. Neoadjuvant treatment is important in imatinib-sensitive subtypes with significant surgery-related morbidity. Multimodal treatment may be considered for metastatic patients with potential complete resection. Next generation inhibitors like ripretinib and avapritinib show promising results in pretreated GIST and GIST with PDGFRA mutations, but the role of multimodal approaches in these settings is yet to be determined.
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This study investigated the impact of diffuse-type Tenosynovial giant cell tumor (D-TGCT) on treatment strategies and quality of life for patients. The results showed that patients who switched to an active treatment strategy had higher scores for pain and interference, while patients who remained off-treatment had lower scores at the 2-year follow-up. These findings are important for guiding the treatment and management of D-TGCT.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
